Karl Bradshaw, Ph.D.

Karl drives Metabolon’s growth strategy by identifying, evaluating, and executing partnering opportunities that align with the company’s strategic goals and technical expertise.

Karl has a deep understanding of global healthcare sector trends for drugs and devices, along with extensive financial analysis experience. Before joining Metabolon, he was a member of AstraZeneca’s corporate development team, responsible for business strategy, including mergers and acquisitions, divestitures, and investments. He honed his financial analysis capabilities at Morgan Stanley as a Vice President in Equity Research, covering the European biotechnology and medical device sectors. Karl earned his Ph.D. in Neuroscience from University College London and holds an MPhil in Bioscience Enterprise from Cambridge University.